Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Telix Pharmaceuticals Limited Unsponsored ADR (TLX) Stock Price & Analysis

14 Followers

TLX Stock Chart & Stats

$9.45-$0.44(-1.87%)
At close: 4:00 PM EST
$9$10$11$12Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$9.36 - $9.57
52-Week Range
$6.28 - $13.11
Previous Close
$9.63
Volume
N/A
Average Volume (3M)
343.70K
Market Cap
$3.23B
Enterprise Value
$4.44B
Total Cash (Recent Filing)
$251.82M
Total Debt (Recent Filing)
$579.64M
Price to Earnings (P/E)
101.9
Beta
1.49
Next Earnings
Feb 19, 2027 (Est.)
EPS Estimate
0.06
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Sustained growth across the core Precision Medicine business indicates strong product demand and expanding commercial execution. The combination of higher group revenue and faster segment growth supports continued scale benefits, investment capacity, and a stronger competitive position over the next several quarters.

Improving Margins And Profitability

Higher gross margins and sharply improved EBITDA show that Telix is converting revenue growth into stronger operating economics. Pricing discipline, manufacturing efficiencies, and operating-cost control can support more durable profitability as the commercial portfolio expands.

Broadening Platform And Pipeline

FDA approval of Pixclara broadens the commercial portfolio beyond the established PSMA franchise and provides entry into neuro-oncology imaging. Combined with multiple clinical programs and isotope capabilities, this diversification can create additional long-term growth avenues.

Bears Say

Negative Recent Cash Generation

The reversal from positive operating and free cash flow in 2023–2024 to materially negative figures in 2025 weakens earnings quality and increases funding reliance. Persistent cash demands could constrain investment flexibility unless commercial growth converts more consistently into cash.

Higher Leverage And Weaker Returns

Debt exceeding equity increases financial risk and reduces flexibility if profitability or cash generation weakens. The combination of higher leverage, a small net loss, and negative return on equity means the expanding asset base has not yet translated into consistently attractive shareholder returns.

Regulatory And Market Expansion Constraints

Zircaix's manufacturing-related regulatory remediation can delay a potentially important product, while high PSMA penetration limits the size of the remaining core market. Growth therefore depends more heavily on successful launches, new indications, and pipeline milestones.

Telix Pharmaceuticals Limited Unsponsored ADR News

TLX FAQ

What was Telix Pharmaceuticals Limited Unsponsored ADR’s price range in the past 12 months?
Telix Pharmaceuticals Limited Unsponsored ADR lowest stock price was $6.28 and its highest was $13.11 in the past 12 months.
What is Telix Pharmaceuticals Limited Unsponsored ADR’s market cap?
Telix Pharmaceuticals Limited Unsponsored ADR’s market cap is $3.23B.
When is Telix Pharmaceuticals Limited Unsponsored ADR’s upcoming earnings report date?
Telix Pharmaceuticals Limited Unsponsored ADR’s next earnings report is estimated for Feb 19, 2027 (not yet confirmed), which is in 100 days.
How were Telix Pharmaceuticals Limited Unsponsored ADR’s earnings last quarter?
Telix Pharmaceuticals Limited Unsponsored ADR released its earnings results on Aug 19, 2026. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.15.
Is Telix Pharmaceuticals Limited Unsponsored ADR overvalued?
According to Wall Street analysts Telix Pharmaceuticals Limited Unsponsored ADR’s price is currently Undervalued.
Does Telix Pharmaceuticals Limited Unsponsored ADR pay dividends?
Telix Pharmaceuticals Limited Unsponsored ADR does not currently pay dividends.
What is Telix Pharmaceuticals Limited Unsponsored ADR’s EPS estimate?
Telix Pharmaceuticals Limited Unsponsored ADR’s EPS estimate is 0.06.
How many shares outstanding does Telix Pharmaceuticals Limited Unsponsored ADR have?
Telix Pharmaceuticals Limited Unsponsored ADR has 340,330,380 shares outstanding.
What happened to Telix Pharmaceuticals Limited Unsponsored ADR’s price movement after its last earnings report?
Telix Pharmaceuticals Limited Unsponsored ADR reported an EPS of $0.17 in its last earnings report, beating expectations of $0.02. Following the earnings report the stock price went up 2.475%.
Which hedge fund is a major shareholder of Telix Pharmaceuticals Limited Unsponsored ADR?
Hedge funds hold Telix Pharmaceuticals Limited Unsponsored ADR shares: the largest hedge-fund position in Telix Pharmaceuticals Limited Unsponsored ADR is 71,886,773 shares, and hedge funds increased their holdings by 708.0 shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology